Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
April 21, 2021 12:46 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore-Bayview facility and...
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
April 15, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
April 04, 2021 22:09 ET
|
Emergent BioSolutions
HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipmentReaffirms 2021 financial guidanceGAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) --...
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
April 02, 2021 08:00 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous...
Emergent BioSolutions to Participate in Investor Conferences
March 01, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
February 18, 2021 16:05 ET
|
Emergent BioSolutions
Reports record fourth quarter and year to date 2020 performance, in line with prior guidanceReaffirms full year 2021 forecast GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) --...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
February 04, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
January 10, 2021 14:00 ET
|
Emergent BioSolutions
Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases...
Emergent BioSolutions to Participate in Investor Conferences
January 04, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
December 29, 2020 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate...